Datamonitor, Nov 2011, Pages: 158
positioning
Physician perception of Enbrel
Clinical and commercial attractiveness
Humira (adalimumab; Abbott/Eisai)
Drug profile
Development overview
SWOT analysis
Product
Datamonitor, March 2009, Pages: 137
detailing of specialist physicians, differentiating by indications is the key to success. Gastroenterologists, rheumatologists and dermatologists have been surveyed on attribute and brand perceptions
Scope
Datamonitor, Dec 2010, Pages: 198
and line of therapy.
- Analysis of 10 key brands, including SSRIs, SNRIs, antipsychotics, and novel antidepressants, based upon physician perception and therapeutic role.
- Detailed review of patient
Panel Intelligence, LLC, Oct 2004
oncologists in the United States
This study will help clients understand therapeutic unmet needs and the productattributes and levels of performance that drive physician preference and prescribing behavior
Datamonitor, March 2009, Pages: 185
and the UK
- Analysis of psoriasis population attributes, physicians prescribing decisions, therapy outcomes and treatment satisfaction
- Brand analysis of key pharmaceuticals used in psoriasis, including
Global Industry Analysts, Inc., Oct 2011, Pages: 373
. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets.
The report profiles 65 companies including many key and niche
GlobalData, Dec 2010, Pages: 66
of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global NASH sector. This report is built using data and information sourced from
Datamonitor, Oct 2008, Pages: 199
to purchase this title
- Targetphysicians more effectively through an understanding of prescribing behavior and its influences.
- Validate new product forecasting based on diagnosis and treatment rates
Datamonitor, Sep 2010, Pages: 204
of which are molecular targeted therapies. While the extent to which these agents will improve patient outcomes remains to be seen, physicians are generally optimistic about the incorporation of these drugs
Datamonitor, Nov 2008, Pages: 362
: LATE-PHASE PIPELINE OVERVIEW 164
Products in Phase III development for CLL 164
Genasense (Oblimersen; Genta) 164
Drug overview 164
Key historical events 165
Datamonitor comments 167
Approval of Genasense
GlobalData, Dec 2010, Pages: 55
and Unmet Need
3.6 Key Takeaway
4 Ovarian Cancer Therapeutics – Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 ProductProfile for the Major Marketed Products in Ovarian
Datamonitor, Dec 2008, Pages: 189
products need to strongly compete on a lower cost profile by lobbing with IVF payers and need to guarantee supply reliability. In Japan, where physicians prescribe 56% of follicle stimulating hormone and 80
Datamonitor, March 2010, Pages: 124
pipeline treatments.
-Identification of key opportunities and threats facing developers of treatments for spinal cord injury.
-Insight from four internationally recognized key opinion leaders in the field
GlobalData, Sep 2011, Pages: 78
. There is a high unmet need which is largely driven by the unavailability of products with adequate efficacy and safety profiles.
Scope
The report provides information on the key drivers and challenges
GlobalData, April 2011, Pages: 63
and efficacy profiles which are disease targeting.
Strong Pipeline Candidates are expected to Intensify Future Competition
The authors research found that there are currently 20 products in different
GlobalData, Jan 2011, Pages: 74
covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.
- Key players covered include Kinetic Concepts, Inc., and Smith & Nephew
GBI Research, March 2011, Pages: 194
Assessment 23
5 Big Medical Device Companies Turn to Life Sustaining Product Portfolio For Growth 24
5.1 Introduction 24
5.2 Company Profiles 25
5.2.1 Medtronic: 25
5.2.2 Boston Scientific: 25
5.2.3 St Jude
Markets and Markets, Aug 2009, Pages: 180
system and others
Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide more than 100
GlobalData, June 2011, Pages: 55
) Therapeutics market. The report identifies the key trends shaping and driving the global Obsessive-Compulsive Disorder (OCD) Therapeutics market. The report also provides insights on the prevalent competitive
